SDF-1 levels increase in primates treated with sulfated glycans but not other mobilizing agents.

SDF-1α levels in primates intravenously injected with 100 mg/kg FucS or DexS or injected with G-CSF, G-CSF plus Flt3 ligand, IL-1β, or antibodies against CD18 or CD49d. Plasma levels of SDF-1α (black bars) peaked at 6 hours with maximum HPC mobilization in 3 M nemestrina treated with sulfated glycans. Other treated primates were tested for SDF-1α when increased numbers of CFCs were highest:M nemestrina treated with G-CSF on day 6, G-CSF/Flt3 ligand on day 5, anti-CD18 on day 3, and baboons treated with humanized anti-CD49d on day 8 or with IL-1β at 2 and 6 hours. The primates were also tested for SDF-1β, but all values remained at baseline levels at all time points tested (G-CSF at 0, 3, 4, 5, 6 days; G-CSF/Flt3 ligand at 0, 4, 5, 6 days; IL-1β at 0, 2, 6, 12 hours, 5 or 7 days; anti-CD18 at 0, 2, 3, 4, 8 days; anti-CD49d at 0, 5, 7 days).